329 related articles for article (PubMed ID: 33686241)
1. Oncogenic functions and therapeutic targeting of EphA2 in cancer.
Wilson K; Shiuan E; Brantley-Sieders DM
Oncogene; 2021 Apr; 40(14):2483-2495. PubMed ID: 33686241
[TBL] [Abstract][Full Text] [Related]
2. Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment.
Nehal M; Khatoon J; Akhtar S; Khan MKA
Mol Biol Rep; 2024 Feb; 51(1):337. PubMed ID: 38393520
[TBL] [Abstract][Full Text] [Related]
3. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
Zhou Y; Sakurai H
Biol Pharm Bull; 2017; 40(10):1616-1624. PubMed ID: 28966234
[TBL] [Abstract][Full Text] [Related]
4. EphA2-dependent molecular targeting therapy for malignant tumors.
Biao-xue R; Xi-guang C; Shuan-ying Y; Wei L; Zong-juan M
Curr Cancer Drug Targets; 2011 Nov; 11(9):1082-97. PubMed ID: 21933105
[TBL] [Abstract][Full Text] [Related]
5. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Chang Q; Jorgensen C; Pawson T; Hedley DW
Br J Cancer; 2008 Oct; 99(7):1074-82. PubMed ID: 18797457
[TBL] [Abstract][Full Text] [Related]
6. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
Veiga RN; de Azevedo ALK; de Oliveira JC; Gradia DF
J Mol Med (Berl); 2024 Apr; 102(4):479-493. PubMed ID: 38393661
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
Mitra S; Duggineni S; Koolpe M; Zhu X; Huang Z; Pasquale EB
Biochemistry; 2010 Aug; 49(31):6687-95. PubMed ID: 20677833
[TBL] [Abstract][Full Text] [Related]
8. Emerging strategies for EphA2 receptor targeting for cancer therapeutics.
Tandon M; Vemula SV; Mittal SK
Expert Opin Ther Targets; 2011 Jan; 15(1):31-51. PubMed ID: 21142802
[TBL] [Abstract][Full Text] [Related]
9. Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer.
Tröster A; Jores N; Mineev KS; Sreeramulu S; DiPrima M; Tosato G; Schwalbe H
ChemMedChem; 2023 Dec; 18(23):e202300420. PubMed ID: 37736700
[TBL] [Abstract][Full Text] [Related]
10. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
11. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z; Doondeea JB; Gholami AM; Janning MC; Lemeer S; Kramer K; Eccles SA; Gollin SM; Grenman R; Walch A; Feller SM; Kuster B
Mol Cell Proteomics; 2011 Dec; 10(12):M111.011635. PubMed ID: 21955398
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
[TBL] [Abstract][Full Text] [Related]
13. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.
Kinch MS; Carles-Kinch K
Clin Exp Metastasis; 2003; 20(1):59-68. PubMed ID: 12650608
[TBL] [Abstract][Full Text] [Related]
14. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.
Ireton RC; Chen J
Curr Cancer Drug Targets; 2005 May; 5(3):149-57. PubMed ID: 15892616
[TBL] [Abstract][Full Text] [Related]
15. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.
Huang J; Hu W; Bottsford-Miller J; Liu T; Han HD; Zand B; Pradeep S; Roh JW; Thanapprapasr D; Dalton HJ; Pecot CV; Rupaimoole R; Lu C; Fellman B; Urbauer D; Kang Y; Jennings NB; Huang L; Deavers MT; Broaddus R; Coleman RL; Sood AK
Clin Cancer Res; 2014 Apr; 20(7):1846-55. PubMed ID: 24486585
[TBL] [Abstract][Full Text] [Related]
17. EphA2: A promising therapeutic target in breast cancer.
Zhao P; Jiang D; Huang Y; Chen C
J Genet Genomics; 2021 Apr; 48(4):261-267. PubMed ID: 33962882
[TBL] [Abstract][Full Text] [Related]
18. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
19. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J
Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452
[TBL] [Abstract][Full Text] [Related]
20. Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer.
Buraschi S; Neill T; Xu SQ; Palladino C; Belfiore A; Iozzo RV; Morrione A
Matrix Biol; 2020 Nov; 93():10-24. PubMed ID: 32417448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]